title: The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effect of preoperative topical latanoprost, bimatoprost, and travoprost administration on postoperative intraocular pressure (IOP) after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.
  
  
  METHODS
  This prospective, randomized, double-masked study included 120 eyes of 120 consecutive, normotensive, uncomplicated cataract patients having phacoemulsification surgery with PC IOL implantation. They were randomized into 1 of 4 treatment groups, each of which had 30 patients. Two (2) h before the surgery, the patients received 0.005% latanoprost (Group 1), 0.004% bimatoprost (Group 2), 0.03% travoprost (Group 3), or placebo (Group 4, artificial tears). IOP was measured at preoperative, 4, 8, and 24 h postoperative with a Goldmann applanation tonometer. The anterior chamber was examined postoperatively 24 h for levels of cell and flare using slit-lamp biomicroscopy.
  
  
  RESULTS
  The preoperative mean IOP was not statistically significant different among the four groups. In Groups 1 and 3, the mean IOP at 4, 8 and 24 h were significantly lower than the control (Group 4; P < 0.05). However, in Group 2, there was no significant difference in IOP during the study period, compared to the control (Group 4; P > 0.05). In addition, the mean postoperative IOP at 24 h in Groups 1 and 3 were significantly lower than the preoperative IOP (P < 0.05). No severe anterior chamber reaction was observed in any group.
  
  
  CONCLUSIONS
  Our findings show that a single-dose topical of latanoprost and travoprost can prevent early postoperative IOP elevation after phacoemulsification surgery without any sideeffects.
authors.affiliation: Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas, Turkey. mkarici@cumhuriyet.edu.tr
authors.forename: Mustafa Kemal
authors.initials: MK
authors.lastname: Arici
authors.forename: Haydar
authors.initials: H
authors.lastname: Erdogan
authors.forename: Ilker
authors.initials: I
authors.lastname: Toker
authors.forename: Ayse
authors.initials: A
authors.lastname: Vural
authors.forename: Aysen
authors.initials: A
authors.lastname: Topalkara
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000577:Amides; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D019654:Lens Implantation, Intraocular; D008055:Lipids / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D018918:Phacoemulsification; D011183:Postoperative Complications; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost